16 research outputs found
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.
PURPOSE: Chemokines are implicated in T-cell trafficking. We mapped the chemokine landscape in advanced stage ovarian cancer and characterized the expression of cognate receptors in autologous dendritic cell (DC)-vaccine primed T cells in the context of cell-based immunotherapy.
EXPERIMENTAL DESIGN: The expression of all known human chemokines in patients with primary ovarian cancer was analyzed on two independent microarray datasets and validated on tissue microarray. Peripheral blood T cells from five HLA-A2 patients with recurrent ovarian cancer, who previously received autologous tumor DC vaccine, underwent CD3/CD28 costimulation and expansion ex vivo. Tumor-specific T cells were identified by HER2/neu pentamer staining and were evaluated for the expression and functionality of chemokine receptors important for homing to ovarian cancer.
RESULTS: The chemokine landscape of ovarian cancer is heterogeneous with high expression of known lymphocyte-recruiting chemokines (CCL2, CCL4, and CCL5) in tumors with intraepithelial T cells, whereas CXCL10, CXCL12, and CXCL16 are expressed quasi-universally, including in tumors lacking tumor-infiltrating T cells. DC-vaccine primed T cells were found to express the cognate receptors for the above chemokines. Ex vivo CD3/CD28 costimulation and expansion of vaccine-primed Tcells upregulated CXCR3 and CXCR4, and enhanced their migration toward universally expressed chemokines in ovarian cancer.
CONCLUSIONS: DC-primed tumor-specific T cells are armed with the appropriate receptors to migrate toward universal ovarian cancer chemokines, and these receptors are further upregulated by ex vivo CD3/CD28 costimulation, which render T cells more fit for migrating toward these chemokines. Clin Cancer Res; 21(12); 2840-50. ©2015 AACR
Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses
“Day-7” myeloid DCs are commonly used in the clinic. However, there is a strong need to develop DCs faster that have the same potent immunostimulatory capacity as “Day-7” myeloid DCs and at the same time minimizing time, labor and cost of DC preparations. Although “2 days” DCs can elicit peptide-specific responses, they have not been demonstrated to engulf, process and present complex whole tumor lysates, which could be more convenient and personalized source of tumor antigens than defined peptides. In this preclinical study, we evaluated the T-cell stimulatory capacity of Day-2, Day-4, and Day-7 cultured monocyte-derived DCs loaded with SKOV3 cell whole lysate prepared by freeze-thaw or by UVB-irradiation followed by freeze-thaw, and matured with lipopolysaccharide (LPS) and interferon (IFN)-gamma. DCs were evaluated for antigen uptake, and following maturation with LPS and IFN-gamma, DCs were assessed for expression of CD80, CD40, CD86, ICAM-1 and CCR7, production of IL-12p70 and IP-10, and induction of tumor-specific T-cell responses. Day-4 and Day-7 DCs exhibited similar phagocytic abilities, which were superior to Day-2 DCs. Mature Day-7 DCs expressed the highest CD40 and ICAM-1, but mature Day-4 DCs produced the most IL-12p70 and IP-10. Importantly, Day-4 and Day-7 DCs derived from ovarian cancer patients stimulated equally strongly tumor-specific T-cell responses. This is the first study demonstrating the highly immunogenic and strong T-cell stimulatory properties of Day-4 myeloid DCs, and provided important preclinical data for rapid development of potent whole tumor lysate-loaded DC vaccines that are applicable to many tumor types
Mobile medical ignorance APP (MOMIA) : a new tool for promoting questions, questioning and questioners (Q3)- anytime, anywhere, anyone
OBJECTIVES/SPECIFIC AIMS: Develop a mobile app for our interactive Virtual Clinical Research Center/Questionarium (VCRC/Q) to elicit, collect and analyze the expanding Unknowns/Questions (\u201cignoramics\u201d) accompanying the exploding Knowns/Answers (informatics) in translational science to investigate, showcase and enhance research advances and inquiry-based training, conferencing, networking and community outreach. METHODS/STUDY POPULATION: Progressive iterations of MoMIA were designed/tested for user friendliness, functionality and efficacy to reprogram our VCRC/Q Web-based platform \u201cgrid\u201d for universal/ubiquitous access to Questions, Questioning and Questioners. Since the mid-1980s, our NIH-funded Curriculum and Summer Institute on Medical Ignorance has involved thousands of diverse questioning medical, undergraduate, high school student and other research trainees as well as professional scientists (including Nobel Laureates) and the general public. RESULTS/ANTICIPATED RESULTS: MoMIA is a Web-based tool (curiosityforall.org) adapted for mobile phones to rapidly and conveniently collect questions from multiple simultaneous users for sorting and future analysis. The VCRC/Q's full menu of resources can be combined with MoMIA to create a customized versions of our Curriculum on Translating Translation and Scientific Questioning in the \u201cExplorarium\u201d site. MoMIA can be demonstrated on your phone at ACTS 2015. DISCUSSION/SIGNIFICANCE OF IMPACT: MoMIA promises to enhance linkage to VCRC/Q resources thereby transforming the grid to promote questions, questioning, and questioners\u2014the engine of translational and all science. Semantics and algorithms are being developed to study the questioning process (\u201ccuriosity\u201d), gather key unanswered questions related to biomedical topics for research/action agendas, and encourage new ways of training, conferencing and networking around the expanding ignorance, thereby counterbalancing the megadata explosion in information
Development of Hot Wire TIG Welding Methods Using Pulsed Current to Heat Filler Wire-Research on Pulse Heated Hot Wire TIG Welding Processes (Report 1)-
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.
We describe a new mechanism regulating the tumor endothelial barrier and T cell infiltration into tumors. We detected selective expression of the death mediator Fas ligand (FasL, also called CD95L) in the vasculature of human and mouse solid tumors but not in normal vasculature. In these tumors, FasL expression was associated with scarce CD8(+) infiltration and a predominance of FoxP3(+) T regulatory (Treg) cells. Tumor-derived vascular endothelial growth factor A (VEGF-A), interleukin 10 (IL-10) and prostaglandin E2 (PGE2) cooperatively induced FasL expression in endothelial cells, which acquired the ability to kill effector CD8(+) T cells but not Treg cells because of higher levels of c-FLIP expression in Treg cells. In mice, genetic or pharmacologic suppression of FasL produced a substantial increase in the influx of tumor-rejecting CD8(+) over FoxP3(+) T cells. Pharmacologic inhibition of VEGF and PGE2 produced a marked increase in the influx of tumor-rejecting CD8(+) over FoxP3(+) T cells that was dependent on attenuation of FasL expression and led to CD8-dependent tumor growth suppression. Thus, tumor paracrine mechanisms establish a tumor endothelial death barrier, which has a critical role in establishing immune tolerance and determining the fate of tumors